We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.

Delisted

GBT was delisted on the 4th of October, 2022.

68 hedge funds and large institutions have $470M invested in Global Blood Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 17 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

59% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 17

15% more funds holding

Funds holding: 5968 (+9)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

58% less capital invested

Capital invested by funds: $1.12B → $470M (-$648M)

Holders
68
Holders Change
+9
Holders Change %
+15.25%
% of All Funds
1.78%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
20
Increased
27
Reduced
17
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$148M +$6.67M +154,129 +3%
PA
2
Perceptive Advisors
New York
$38.4M +$11.5M +264,830 +29%
DM
3
Deerfield Management
New York
$37.6M +$11.8M +273,191 +31%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$32.3M +$13.6M +314,788 +46%
PHS
5
PFM Health Sciences
California
$22.8M -$2.37M -54,829 -7%
JHIU
6
Janus Henderson Investors US
Colorado
$22.6M +$30.3M +699,384 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$16.3M +$19.7M +454,940 +934%
FCMI
8
Foresite Capital Management III
California
$14.9M +$19.9M +460,000 New
RCM
9
RA Capital Management
Massachusetts
$14.8M
BBA
10
Baker Bros. Advisors
New York
$12.9M +$8.66M +200,000 +100%
Jennison Associates
11
Jennison Associates
New York
$10.1M -$2.46M -56,709 -15%
GGHC
12
Gilder Gagnon Howe & Co
New York
$9.6M +$12.9M +297,053 New
RG
13
Redmile Group
California
$7.07M -$1.91M -44,174 -17%
UBS Group
14
UBS Group
Switzerland
$6.96M +$9.33M +215,431 New
DCM
15
Driehaus Capital Management
Illinois
$6.51M -$1.82M -42,137 -17%
SM
16
Sabby Management
Florida
$6.45M
JP Morgan Chase
17
JP Morgan Chase
New York
$6.06M -$1.13M -26,075 -12%
RI
18
RTW Investments
New York
$5.66M +$3.58M +82,757 +90%
BFA
19
BlackRock Fund Advisors
California
$5.53M +$275K +6,354 +4%
EAM
20
Eventide Asset Management
Massachusetts
$5.33M +$6.47M +149,521 +966%
VMI
21
VHCP Management II
New York
$4.58M +$6.13M +141,611 New
IHM
22
Iguana Healthcare Management
New York
$3.56M +$1.95M +45,000 +69%
State Street
23
State Street
Massachusetts
$2.85M +$558K +12,875 +17%
BIT
24
BlackRock Institutional Trust
California
$2.49M +$603K +13,927 +22%
Asset Management One
25
Asset Management One
Japan
$2.46M -$155K -3,573 -5%

GBT Hedge Fund Activity: Q4 2015 in Review

68 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2015, worth a combined $470M — down 58% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new GBT positions and 10 closed out — a net gain of 10 holders — while 27 added to existing stakes and 17 trimmed.

The largest buyer was Janus Henderson Investors US, opening a new position worth an estimated $30.3M. The largest seller was RS Investment Management, exiting entirely with an estimated $13.4M sold.

  • 68 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2015, up from 59 in Q3 2015.
  • Funds reported $470M of Global Blood Therapeutics, Inc. stock for Q4 2015, down 58% quarter-over-quarter.
  • 20 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2015 and 10 closed out, a net change of +10 holders.
  • The largest Global Blood Therapeutics, Inc. buyer in Q4 2015 was Janus Henderson Investors US, an estimated $30.3M added.
  • The largest Global Blood Therapeutics, Inc. seller in Q4 2015 was RS Investment Management, an estimated $13.4M sold.

Based on aggregated 13F filings for Q4 2015.